VYNE - VYNE Therapeutics to Host Virtual R&D Day Event on November 9 2023 | Benzinga
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE's clinical development plans
Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo
BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m. ET. To register, click here.
The event will feature a presentation from Dr. Amit Pandya, former President of the Global Vitiligo Foundation. VYNE management will discuss the final results from the Phase 1b trial for VYN201 in patients with nonsegmental vitiligo. In addition, VYNE management will review the preclinical data for its oral BD2-selective BET inhibitor, VYN202, in psoriasis and rheumatoid arthritis and discuss its development plans for both programs.
A live question and answer session will follow the formal presentation.
About Dr. Amit Pandya
Dr. Amit Pandya recently served as President of the Global Vitiligo Foundation and is currently Staff Dermatologist, Department of Dermatology, Palo Alto Foundation Medical Group.
Dr. Pandya's practice focuses on patients with vitiligo, ...